StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) stock

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.52−4.33 (-3.44%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

Kymera Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Kymera Therapeutics's total assets was $1.77B at Sep 30, 2026. For fiscal 2025 it was $1.74B, up 78.2% from the year before. The highest annual figure on record is $1.74B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.74B+78.2%
FY2024Dec 31, 2024$978.04M+69.9%
FY2023Dec 31, 2023$575.76M-4.5%
FY2022Dec 31, 2022$603.13M-0.5%
FY2021Dec 31, 2021$605.91M+24.4%
FY2020Dec 31, 2020$487.18M+317.5%
FY2019Dec 31, 2019$116.70M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.77B+60.4%
Q2 FY2026Jun 30, 2026$1.65B+45.5%
Q1 FY2026Mar 31, 2026$1.67B+81.7%
Q4 FY2025Dec 31, 2025$1.74B+78.2%
Q3 FY2025Sep 30, 2025$1.10B+6.5%
Q2 FY2025Jun 30, 2025$1.13B+36.9%
Q1 FY2025Mar 31, 2025$918.31M+5.8%
Q4 FY2024Dec 31, 2024$978.04M+69.9%
Q3 FY2024Sep 30, 2024$1.03B+87.3%
Q2 FY2024Jun 30, 2024$826.02M+41.9%
Q1 FY2024Mar 31, 2024$868.25M+41.4%
Q4 FY2023Dec 31, 2023$575.76M-4.5%
Q3 FY2023Sep 30, 2023$552.38M-13.5%
Q2 FY2023Jun 30, 2023$581.95M+11.2%
Q1 FY2023Mar 31, 2023$613.91M+9.0%
Q4 FY2022Dec 31, 2022$603.13M-0.5%
Q3 FY2022Sep 30, 2022$638.47M-0.6%
Q2 FY2022Jun 30, 2022$523.42M+20.5%
Q1 FY2022Mar 31, 2022$563.06M+21.2%
Q4 FY2021Dec 31, 2021$605.91M+24.4%
Q3 FY2021Sep 30, 2021$642.45M+26.6%
Q2 FY2021Jun 30, 2021$434.39M+272.2%
Q1 FY2021Mar 31, 2021$464.55M–
Q4 FY2020Dec 31, 2020$487.18M–
Q3 FY2020Sep 30, 2020$507.36M–
Q4 FY2019Dec 31, 2019$116.70M–

More Kymera Therapeutics figures

See a number that looks wrong?